Free Trial

Vaxart Q1 2024 Earnings Report

Vaxart logo
$0.38 +0.03 (+8.34%)
As of 04/3/2025 04:00 PM Eastern

Vaxart EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Vaxart Revenue Results

Actual Revenue
$2.18 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxart Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Vaxart Earnings Headlines

Critical Review: NKGen Biotech (NYSE:NKGN) vs. Vaxart (NASDAQ:VXRT)
B. Riley Comments on Vaxart's Q1 Earnings (NASDAQ:VXRT)
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Vaxart price target lowered to $2 from $2.50 at B. Riley
See More Vaxart Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxart? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxart and other key companies, straight to your email.

About Vaxart

Vaxart (NASDAQ:VXRT), a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

View Vaxart Profile

More Earnings Resources from MarketBeat